BioCentury | Dec 19, 2011
Clinical News

ATx08-001: Phase II data

...U.S. Phase II trial in 61 patients showed that twice-daily 2.5 and 7.5 mg oral ATx08-001...
...events or due to the need for rescue medications. Aestus has exclusive, worldwide rights to ATx08-001...
...Therapeutics Inc. , North Brunswick, N.J. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: ATx08-001 (formerly FK614...
BioCentury | Sep 26, 2011
Company News

Aestus Therapeutics, Astellas deal

...BioCentury, June 14, 2010). Aestus said the deal adds to its pain portfolio, which includes ATx08-001...
BioCentury | Sep 20, 2011
Company News

Prosidion, Aestus partner for pain compound

...Pharmaceuticals Inc. last year. Aestus said the deal adds to its pain portfolio, which includes ATx08-001...
BioCentury | Feb 28, 2011
Clinical News

ATx08-001: Phase II started

...and high-doses of oral ATx08-001 in about 60 patients. Aestus has exclusive, worldwide rights to ATx08-001...
...Therapeutics Inc. , North Brunswick, N.J. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: ATx08-001 (formerly FK614...
BioCentury | Jul 5, 2010
Company News

Aestus Therapeutics, Astellas deal

...Astellas granted Aestus an exclusive, worldwide license to FK614 . Aestus, which renamed the compound ATx08-001...
BioCentury | Mar 8, 2004
Strategy

The Fuji-Yama merger

...III (U.S.) Fujisawa Cardiome Co-development Conivaptan (YM087) Chronic heart failure Ph II (EU, U.S.) Yamanouchi FK614...
Items per page:
1 - 6 of 6